| Name | Title | Contact Details |
|---|
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
The Canadian Cancer Research Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.
Spine Vision is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.